Mackenzie Financial Corp Intellia Therapeutics, Inc. Transaction History

Mackenzie Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 07, 2022	SELL	$53.92 - $71.7 $14,234 - $18,928	-264 Reduced 5.09%	4,922 $275,000
Q2 2022 Aug 10, 2022	BUY	$38.49 - $76.21 $53,539 - $106,008	1,391 Added 36.65%	5,186 $268,000
Q1 2022 May 13, 2022	BUY	$58.27 - $118.99 $7,982 - $16,301	137 Added 3.75%	3,795 $276,000
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $201,318 - $276,443	-1,998 Reduced 35.33%	3,658 $433,000
Q3 2021 Nov 08, 2021	BUY	$132.37 - $176.78 $466,074 - $622,442	3,521 Added 164.92%	5,656 $759,000
Q2 2021 Aug 11, 2021	BUY	$60.88 - $161.91 $129,978 - $345,677	2,135 New	2,135 $346,000

317

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $835M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.